Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + gemcitabine + liposomal doxorubicin + bevacizumab
- Development stage
- Preclinical
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy regimen consisting of paclitaxel (a taxane), gemcitabine (a nucleoside analog), liposomal doxorubicin (an anthracycline in liposomal formulation), and bevacizumab (an anti-VEGF monoclonal antibody). While not established as a standard four-drug combination, various combinations of these agents are used in the treatment of recurrent ovarian cancer. Bevacizumab inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF), while the chemotherapy agents work through different mechanisms to inhibit cancer cell growth and division.
02
Targets
DNADNA polymerase familyVEGFA (Vascular endothelial growth factor A)TUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on paclitaxel + gemcitabine + liposomal doxorubicin + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + gemcitabine + liposomal doxorubicin + bevacizumab.